243 related articles for article (PubMed ID: 35959505)
1. Personalized medicine with drugs targeting the underlying protein defect in cystic fibrosis: is monitoring of treatment response necessary?
Niedermayr K; Gasser V; Rueckes-Nilges C; Appelt D; Eder J; Fuchs T; Naehrlich L; Ellemunter H
Ther Adv Chronic Dis; 2022; 13():20406223221108627. PubMed ID: 35959505
[TBL] [Abstract][Full Text] [Related]
2. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two
Graeber SY; Vitzthum C; Pallenberg ST; Naehrlich L; Stahl M; Rohrbach A; Drescher M; Minso R; Ringshausen FC; Rueckes-Nilges C; Klajda J; Berges J; Yu Y; Scheuermann H; Hirtz S; Sommerburg O; Dittrich AM; Tümmler B; Mall MA
Am J Respir Crit Care Med; 2022 Mar; 205(5):540-549. PubMed ID: 34936849
[No Abstract] [Full Text] [Related]
3. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One
Wainwright C; McColley SA; McNally P; Powers M; Ratjen F; Rayment JH; Retsch-Bogart G; Roesch E; Ahluwalia N; Chin A; Chu C; Lu M; Menon P; Waltz D; Weinstock T; Zelazoski L; Davies JC
Am J Respir Crit Care Med; 2023 Jul; 208(1):68-78. PubMed ID: 37154609
[No Abstract] [Full Text] [Related]
4. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for
Mall MA; Brugha R; Gartner S; Legg J; Moeller A; Mondejar-Lopez P; Prais D; Pressler T; Ratjen F; Reix P; Robinson PD; Selvadurai H; Stehling F; Ahluwalia N; Arteaga-Solis E; Bruinsma BG; Jennings M; Moskowitz SM; Noel S; Tian S; Weinstock TG; Wu P; Wainwright CE; Davies JC
Am J Respir Crit Care Med; 2022 Dec; 206(11):1361-1369. PubMed ID: 35816621
[No Abstract] [Full Text] [Related]
5. Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.
Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
mBio; 2024 Feb; 15(2):e0193523. PubMed ID: 38275294
[TBL] [Abstract][Full Text] [Related]
6. Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del.
Lopez A; Daly C; Vega-Hernandez G; MacGregor G; Rubin JL
J Cyst Fibros; 2023 Jul; 22(4):607-614. PubMed ID: 36849331
[TBL] [Abstract][Full Text] [Related]
7. Real world outcomes of CFTR modulator therapy in Australian adults and children.
Kuek S; McCullagh A; Paul E; Armstrong D
Pulm Pharmacol Ther; 2023 Oct; 82():102247. PubMed ID: 37574040
[TBL] [Abstract][Full Text] [Related]
8. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One
Zemanick ET; Taylor-Cousar JL; Davies J; Gibson RL; Mall MA; McKone EF; McNally P; Ramsey BW; Rayment JH; Rowe SM; Tullis E; Ahluwalia N; Chu C; Ho T; Moskowitz SM; Noel S; Tian S; Waltz D; Weinstock TG; Xuan F; Wainwright CE; McColley SA
Am J Respir Crit Care Med; 2021 Jun; 203(12):1522-1532. PubMed ID: 33734030
[No Abstract] [Full Text] [Related]
9. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two
Graeber SY; Renz DM; Stahl M; Pallenberg ST; Sommerburg O; Naehrlich L; Berges J; Dohna M; Ringshausen FC; Doellinger F; Vitzthum C; Röhmel J; Allomba C; Hämmerling S; Barth S; Rückes-Nilges C; Wielpütz MO; Hansen G; Vogel-Claussen J; Tümmler B; Mall MA; Dittrich AM
Am J Respir Crit Care Med; 2022 Aug; 206(3):311-320. PubMed ID: 35536314
[No Abstract] [Full Text] [Related]
10. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one
Daines CL; Tullis E; Costa S; Linnemann RW; Mall MA; McKone EF; Polineni D; Quon BS; Ringshausen FC; Rowe SM; Selvadurai H; Taylor-Cousar JL; Withers NJ; Ahluwalia N; Moskowitz SM; Prieto-Centurion V; Tan YV; Tian S; Weinstock T; Xuan F; Zhang Y; Ramsey B; Griese M;
Eur Respir J; 2023 Dec; 62(6):. PubMed ID: 37945033
[TBL] [Abstract][Full Text] [Related]
11. Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis.
Olivier M; Kavvalou A; Welsner M; Hirtz R; Straßburg S; Sutharsan S; Stehling F; Steindor M
Front Pharmacol; 2023; 14():1176815. PubMed ID: 37229253
[No Abstract] [Full Text] [Related]
12. Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis.
Stekolchik E; Saul D; Chidekel A
Respir Med Case Rep; 2022; 40():101775. PubMed ID: 36411821
[TBL] [Abstract][Full Text] [Related]
13. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis.
Schechter MS; Sabater-Anaya N; Oster G; Weycker D; Wu H; Arteaga-Solis E; Bagal S; McGarry LJ; Van Brunt K; Geiger JM
Pulm Ther; 2023 Dec; 9(4):479-498. PubMed ID: 37874528
[TBL] [Abstract][Full Text] [Related]
14. Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis.
Beck MR; Hornick DB; Pena TA; Singh SB; Wright BA
Pediatr Pulmonol; 2023 May; 58(5):1569-1573. PubMed ID: 36807558
[TBL] [Abstract][Full Text] [Related]
15. A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation.
McKone EF; DiMango EA; Sutharsan S; Barto TL; Campbell D; Ahluwalia N; Higgins M; Owen CA; Tullis E
J Cyst Fibros; 2021 Mar; 20(2):234-242. PubMed ID: 33339768
[TBL] [Abstract][Full Text] [Related]
16. Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.
Sadras I; Kerem E; Livnat G; Sarouk I; Breuer O; Reiter J; Gileles-Hillel A; Inbar O; Cohen M; Gamliel A; Stanleigh N; Gunawardena T; Bartlett C; Gonska T; Moraes T; Eckford PDW; Bear CE; Ratjen F; Kerem B; Wilschanski M; Shteinberg M; Cohen-Cymberknoh M
J Cyst Fibros; 2023 Nov; 22(6):1062-1069. PubMed ID: 37331863
[TBL] [Abstract][Full Text] [Related]
17. Theratyping of the Rare CFTR Variants E193K and R334W in Rectal Organoid-Derived Epithelial Monolayers.
Ciciriello F; Bijvelds MJC; Alghisi F; Meijsen KF; Cristiani L; Sorio C; Melotti P; Fiocchi AG; Lucidi V; De Jonge HR
J Pers Med; 2022 Apr; 12(4):. PubMed ID: 35455747
[TBL] [Abstract][Full Text] [Related]
18. Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study.
Bower JK; Volkova N; Ahluwalia N; Sahota G; Xuan F; Chin A; Weinstock TG; Ostrenga J; Elbert A
J Cyst Fibros; 2023 Jul; 22(4):730-737. PubMed ID: 36963986
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review.
Kapouni N; Moustaki M; Douros K; Loukou I
Children (Basel); 2023 Mar; 10(3):. PubMed ID: 36980112
[TBL] [Abstract][Full Text] [Related]
20. Long-term clinical outcomes of elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis and advanced pulmonary disease.
Savi D; Lucca F; Tridello G; Meneghelli I; Comello I; Tomezzoli S; Signorini M; Proietti E; Cucchetto G; Volpi S; Cipolli M
Respir Med; 2023; 219():107406. PubMed ID: 37690570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
